I've been covering more and more UK-based or domiciled companies as of late. This has a number of reasons, but the foremost of them is that I am simply investing more in these companies. I've been pushing capital into UK-based energy, telecommunications, finance, and consumer staples, andAnalyst’s Disclosure:I/we have a beneficial long position in the shares of SEMHF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receivi ...

LivaNova (LIVN) FY 2025 Annual General Meeting June 11, 2025 10:00 AM ET Speaker0 Hello and welcome to the Annual Meeting of Shareholders of LivaNova plc. Please note that today's meeting is being recorded. During the meeting, we'll have a question and answer session. You can submit questions or comments at any time by clicking on the Q and A icon. It is now my pleasure to turn today's meeting over to Mr. Bill Cosi, Chair of the Board Speaker1 of Speaker0 LivaNova. Mr. Cozzi, the floor is yours. Speaker2 Th ...

LivaNova (LIVN) 2025 Conference June 05, 2025 03:10 PM ET Speaker0 Our next session here, Matt Taylor, the U. Medical Supplies and Devices analyst here at Jefferies. And I'm joined by the management team from LivaNova, including Vlad Makataria, CEO, and Phil Kowalsik, the CSO, Brianna Gottland, who runs the Investor Relations Program. So we'll have about a half an hour for moderated Q and A with the team. And I just want to thank everybody for your interest, and thanks for coming. So to get started, we've a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

LivaNova (LIVN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Briana Gotlin - VP-IRVladimir Makatsaria - CEOAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - Chief Financial OfficerRick Wise - Managing Director - Medical Technology & SuppliesDavid Roman - Managing DirectorStephanie Bolton - President of Global Epilepsy Conference Call Participants Adam Maeder - Senior Research AnalystMichael Sarcone - AnalystMike Matson - Senior Equity Research AnalystDavid Rescott - Senior Rese ...

LivaNova (LIVN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Speaker0 Good day, ladies and gentlemen, and welcome to the LivaNova plc First Quarter twenty twenty five Earnings Conference Call. My name is Emily, and I'll be coordinating your call today. As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Ms. Brianna Gottlin, Levernova's Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, and welcome to our conference ...

LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.33%. A quarter ago, it was expected that this medical technology company would post earnings of $0.80 per share when it actually produced earnings of $0.81, delivering a surprise of 1.25%.Over the last four quarters, t ...

1 Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events, and involve ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance London, May 7, 2025 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights (1) Constant-currency percent change, organic revenue percent change, organic revenue, adjusted operating income, adjusted diluted earnings per share, and adjusted free cash flow are non- ...

业绩表现 - 公司季度每股收益为1.36美元 超出Zacks共识预期1.24美元 同比增长76.6%（从0.77美元）[1] - 季度营收达3.72亿美元 超出共识预期1.29% 但同比下滑24.5%（从4.928亿美元）[2] - 最近四个季度均超过EPS预期 最近两次季度盈利超预期幅度分别为9.68%和20.81%[1][2] 市场反应 - 年初至今股价下跌1.5% 表现优于标普500指数（-3.9%）[3] - 当前Zacks评级为2（买入） 预计短期内将跑赢大盘[6] 行业动态 - 所属医疗仪器行业在Zacks行业排名中位列前25% 历史数据显示前50%行业表现是后50%的两倍以上[8] - 同业公司LivaNova预计季度EPS为0.75美元（同比+2.7%） 营收预计3.0063亿美元（同比+1.9%）[9] 未来展望 - 当前市场共识预期：下季度EPS 1.27美元（营收3.7212亿美元） 本财年EPS 5.28美元（营收15.2亿美元）[7] - 盈利预测修订趋势向好 但具体方向可能随最新财报发布后调整[6] - 管理层在财报电话会中的评论将影响股价短期走势[3]